Table of Contents Author Guidelines Submit a Manuscript
Analytical Cellular Pathology
Volume 2017 (2017), Article ID 9404057, 20 pages
Review Article

Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials

Ming Hao,1,2 Richard Wang,1,2 and Wen Wang1,2

1Cellular Biomedicine Group, 333 Guiping Road, Shanghai 200233, China
2Cellular Biomedicine Group, 19925 Stevens Creek Blvd, Suite 100, Cupertino, CA 95014, USA

Correspondence should be addressed to Wen Wang; moc.puorgdemoibllec@gnaw.llewxam

Received 22 September 2016; Revised 6 December 2016; Accepted 8 December 2016; Published 17 January 2017

Academic Editor: Alain Chapel

Copyright © 2017 Ming Hao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Because the human heart has limited potential for regeneration, the loss of cardiomyocytes during cardiac myopathy and ischaemic injury can result in heart failure and death. Stem cell therapy has emerged as a promising strategy for the treatment of dead myocardium, directly or indirectly, and seems to offer functional benefits to patients. The ideal candidate donor cell for myocardial reconstitution is a stem-like cell that can be easily obtained, has a robust proliferation capacity and a low risk of tumour formation and immune rejection, differentiates into functionally normal cardiomyocytes, and is suitable for minimally invasive clinical transplantation. The ultimate goal of cardiac repair is to regenerate functionally viable myocardium after myocardial infarction (MI) to prevent or heal heart failure. This review provides a comprehensive overview of treatment with stem-like cells in preclinical and clinical studies to assess the feasibility and efficacy of this novel therapeutic strategy in ischaemic cardiomyopathy.